This is the third edition of the guidelines – the last coming in 2014 – providing a resource and guidance specifically for primary care practitioners about how to plan care for childhood cancer survivors. “A care plan just really encourages coordination, especially if a child has a very complicated post-cancer treatment history with a lot […]
Available from Guideline Central, the free, quick-reference print and digital pocket guide covers the most recent American Society of Clinical Oncology (ASCO) Hepatocellular Carcinoma Guidelines. Accessed by web and offline mobile devices, the pocket guide covers key points, treatment, first- and second-line therapies, a downloadable PDF, and links to other resources in advanced hepatocellular carcinoma.
The American Society of Clinical Oncology (ASCO) published a guideline update about the selection of optimal adjuvant chemotherapy regimens and targeted therapy for early breast cancer, namely trastuzumab emtansine. In a second recommendation, the ASCO guideline addressed the use of biosimilar forms of trastuzumab—five of which have been approved by the FDA.
Research from 20 years (2000 -2020) of studies (293) inform the evidence base for this guideline from ASCO, which addressed six main clinical questions/subquestions on preoperative evaluations, surgical diagnostic and therapeutic procedures, appropriate radiotherapy techniques, the role of systemic therapy, and follow-up evaluations.
An update from the original ASCO guideline on this topic published in 2012, 60 studies, primarily retrospective, were included in the review. New to this version of the guideline, the Panel offers recommendations on approved doses of immunotherapy and targeted therapies that can be offered to obese patients with cancer.
A systematic review identified 204 eligible publications from 2000 through 2017, with much of the evidence consisting of systematic reviews of observational data, consensus guidelines, case series, and case reports. Due to the paucity of high-quality evidence on management of immune-related adverse events, recommendations are based on expert consensus.